Abstract：【Objective】 To investigate the clinical efficacy of different doses of Sakubatroxvalsartan in the treatment of hypertensive patients with CHF. 【Methods】 From January 2019 to January 2022, 100 patients with hypertension and CHF admitted to the Affiliated Hospital of Yan'an University were randomly divided into a large dose group (conventional treatment + Sakubatroxvalsartan tablets 100 mg) and a small dose group (conventional treatment + Sakubatroxvalsartan tablets 50 mg) according to the random number table. Two groups were compared in terms of efficacy, serum levels of high sensitivity C-reactive protein (hs-CRP), endothelin-1 (ET-1), N-terminal-proBNP, cardiac function indicators, and adverse reactions after treatment. 【Results】The total effective rate of the high-dose group was 90.00% (45/50), significantly higher than the 72.00% (36/50) of the low-dose group, with a statistically significant difference (P<0.05). After treatment, the serum levels of hs-CRP and ET-1 in both groups were lower than those before treatment, and the high-dose group was lower than the low-dose group, with a statistically significant difference (P<0.05); LVEDD and NT-proBNP in both groups were lower than those before treatment, while LVEF was higher than treatment; The indicators of the high-dose group were better than those of the low-dose group, and the difference was statistically significant (P<0.05). The incidence of adverse reactions was 20.00% (10/50) in the high-dose group and 10.00% (5/50) in the low-dose group, with no statistically significant difference (P>0.05). 【Conclusion】High dose Sakubatroxvalsartan is effective in the treatment of hypertension with CHF. It can reduce the level of inflammatory factors, improve the heart function of patients, and has good safety.
董旺黎, 雷杰喻, 师文涛. 不同剂量沙库巴曲缬沙坦治疗高血压合并慢性心力衰竭患者的临床疗效[J]. 医学临床研究, 2023, 40(7): 976-978.
DONG Wang-li, LEI Jie-yu, SHI Wen-tao. Clinical Efficacy of Different Doses of Sakubactrovalsartan in Patients with Hypertension Complicated with Chronic Heart Failure. JOURNAL OF CLINICAL RESEARCH, 2023, 40(7): 976-978.
2023, Vol. 40 
